Scott Horner


Scott is a Managing Director at Middleland Capital where he is responsible for portfolio management and evaluating investment opportunities in agriculture and biotechnology.  Scott currently sits on the Board of Directors  of Mycotechnology Inc., Plant Response Biotech, and Blue Prairie Brands, and is a Board observer on Advanced Animal Diagnostics, Vive Crop Protection, ZeaKal, and Virgin Plants Inc.  Prior to joining Middleland, Scott was a Managing Director at Third Security, LLC, where he was responsible for assessing potential investments in the biotechnology and pharmaceutical sectors.  He also worked with many portfolio companies of Third Security’s managed investment funds providing business intelligence and operational support, and served on the Board of Directors of Synchrony Inc. (acquired by Dresser-Rand Corp.).  In addition to portfolio management duties, he also took on interim operating roles within several portfolio companies, including President and Chief Executive Officer of Pinnacle Pharmaceuticals, VP Chemistry, Intrexon Corporation (NYSE:XON) and VP Business Development, Intrexon Corporation.  Prior to joining Third Security, he was a founder and Chief Scientific Officer at Pathologics, LLC, a point of care diagnostics company located in Rochester, NY.  Scott  received his Ph.D. in Bioorganic Chemistry and an M.S. in Biophysics from the University of Rochester and a B.S. in Biochemistry from the State University of New York at Albany.